Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Invest New Drugs. 2015 Mar 31;33(3):621–631. doi: 10.1007/s10637-015-0226-6

Table 1.

Characteristics of patients with NSCLC according to Anti-EGFR pretreatment

All NSCLC Patients
(n=16)
Anti-EGFR
pretreated
(n=10)
No Anti-EGFR
pretreatment
(n=6)
p
Age, (Mean±SD (Median,
[IQR])), year
59.3±13.7 (58.5 [51.5-
70.3])
58.9±16.9 (57.0 [49.3-
74.0])
59.8±7.0 (60.0 [54.0-
63.8])
0.96
Male, n(%) 6 (37%) 3 (30%) 3 (50%) 0.44
Female, n(%) 10 (63%) 7 (70%) 3 (50%)
ECOG status
 0 6 (38%) 3 (30%) 3 (50%) 0.44
 1 9 (56%) 6 (60%) 3 (50%) 0.71
 2 1 (6%) 1 (10%) 0 1.00
EGFR Mutation status
 +ve 1 (6%) 1 (10%) 0 (0%) 1.00
 −ve 13 (86%) 7 (70%) 6 (100%) 0.25
 Not done 2 (13%) 2 (20%) 0 (100%) 0.50
KRAS Mutation status
 +ve 8 (50%) 5 (50%) 3 (50%) 1.00
 −ve 4 (25%) 3 (30%) 1 (17%) 1.00
 Not done 4 (25%) 2 (20%) 2 (33%) 0.60
Prior Chemotherapies
(Mean±SD (Median, [IQR]))
3.4±2.4
(3.0 [2.0-4.3])
3.6±2.3
(3.5 [2.3-4.8])
3.2±2.6
(3.0 [2.3-3.0])
0.58

ECOG: Eastern Cooperative Oncology Group, IQR: inter-quartile range